However, enthusiasm for use of TNF-α inhibitors for treatment of patients with cardiovascular risk remains controversial as a few large multi-center comparative studies fail to demonstrate benefit for cardiovascular-related events, heart failure, death risk and improved cardiovascular outcomes (37–39). Here, TNF is linked to heart failure.